LEEI Consortium

9

Years of experience

3

Partners

1

Aim

.ugb-3e0bf9a hr.ugb-divider__hr{background-color:#f15b55 !important;height:4px !important;width:90% !important;margin-left:auto !important;margin-right:auto !important}

The „LEEI Consortium“ brings together three dynamic partners – KyooBe Tech, Bausch+Ströbel, and Fraunhofer – in a thrilling interdisciplinary collaboration.

 In a groundbreaking and forward-thinking methodology, we employ electron beams for the inactivation of pathogens. This revolutionary approach not only enhances production efficiency, but also elevates vaccine quality, removing hazardous chemicals and ensures process reproducibilitvy.

.ugb-394280c hr.ugb-divider__hr{background-color:#f15b55 !important;height:4px !important;width:90% !important;margin-left:auto !important;margin-right:auto !important}

.ugb-d6ad10e hr.ugb-divider__hr{margin-left:auto !important;margin-right:auto !important}

KyooBe Tech is an emerging engineering company focusing on the development of innovative manufacturing platforms, that drives the pharmaceutical production of tomorrow. With an interdisciplinary team of motivated engineers and biotechnologists, we develop high-quality technological solutions for biological challenges in vaccines and cell and gene therapy. Our vision is to enable access of next-generation therapeutic methods to a broader patient population.

.ugb-4b61956 hr.ugb-divider__hr{margin-left:auto !important;margin-right:auto !important}

KyooBe Tech is an emerging engineering company focusing on the development of innovative manufacturing platforms, that drives the pharmaceutical production of tomorrow. With an interdisciplinary team of motivated engineers and biotechnologists, we develop high-quality technological solutions for biological challenges in vaccines and cell and gene therapy. Our vision is to enable access of next-generation therapeutic methods to a broader patient population.

.ugb-4271aec hr.ugb-divider__hr{margin-left:auto !important;margin-right:auto !important}

Four Fraunhofer institutes lead the scientific forefront of this technology, continuously innovating and exploring new applications of LEEI-technologies. They conduct extensive pathogen studies to identify potential vaccine candidates, while also spearheading the development of the prototype system.

.ugb-c10ba0c hr.ugb-divider__hr{margin-left:auto !important;margin-right:auto !important}

.ugb-a6c7a84 hr.ugb-divider__hr{margin-left:auto !important;margin-right:auto !important}

Our journey

1/1/2019

First virus inactivation

2012
1/1/2019

Innovation project granted by the Fraunhofer innovations fund

2013
1/1/2019

Filing of LEEI patent family 

2014
1/1/2019

Grant by Bill & Melinda Gates Foundation

2016
1/1/2019

Licensing deal with Bausch+Ströbel

2019
1/1/2019

Foundation of KyooBe Tech GmbH

2020
1/1/2019

Launch of KyooBe Techs first LEEI 2.0 prototype  

2022
1/1/2019

KyooBe Tech enters the market with it’s first Lab Scale Pilot Device

2024

Parcipitate in a new generation of vacccine manufacturing!

Get in contact to learn and participate!